ursodiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2797	128-13-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: urosiol ursodiol ursocol ursodeoxycholic acid ursodesoxycholic acid ursolvan ursacholic acid deoxyursocholic acid	An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. Molecular weight: 392.58 Formula: C24H40O4 CLOGP: 4.51 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 77.76 ALOGS: -4.30 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

urosiol
ursodiol
ursocol
ursodeoxycholic acid
ursodesoxycholic acid
ursolvan
ursacholic acid
deoxyursocholic acid

An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.

Molecular weight: 392.58
Formula: C24H40O4
CLOGP: 4.51
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 77.76
ALOGS: -4.30
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.75	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	38.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1987	FDA	ACTAVIS LABS UT INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	370.23	12.05	241	28078	34180	46623563
Blood bilirubin increased	223.71	12.05	177	28142	34007	46623736
Ascites	194.64	12.05	168	28151	36416	46621327
Hepatic encephalopathy	182.22	12.05	99	28220	10058	46647685
Pruritus	182.13	12.05	432	27887	241920	46415823
Hepatic failure	170.79	12.05	150	28169	33266	46624477
Liver disorder	156.83	12.05	150	28169	37096	46620647
Aspartate aminotransferase increased	136.11	12.05	201	28118	78499	46579244
Platelet count decreased	133.68	12.05	227	28092	99797	46557946
Jaundice	119.20	12.05	115	28204	28730	46629013
Alanine aminotransferase increased	115.87	12.05	199	28120	88252	46569491
Primary biliary cholangitis	113.96	12.05	38	28281	1133	46656610
Hepatocellular carcinoma	113.49	12.05	48	28271	2791	46654952
Graft versus host disease	109.31	12.05	61	28258	6527	46651216
Venoocclusive liver disease	106.83	12.05	52	28267	4199	46653544
Cholangitis	99.25	12.05	51	28268	4623	46653120
Infective pulmonary exacerbation of cystic fibrosis	97.69	12.05	68	28251	10739	46647004
Hepatic cirrhosis	95.50	12.05	78	28241	15654	46642089
Rheumatoid arthritis	92.48	12.05	17	28302	240198	46417545
Drug ineffective	86.82	12.05	176	28143	677662	45980081
Cytomegalovirus infection	85.83	12.05	78	28241	18066	46639677
Disseminated intravascular coagulation	82.74	12.05	78	28241	18927	46638816
Blood alkaline phosphatase increased	81.50	12.05	110	28209	39499	46618244
Drug hypersensitivity	75.24	12.05	27	28292	243798	46413945
Pain	73.51	12.05	110	28209	476838	46180905
Cholestasis	73.37	12.05	86	28233	26807	46630936
Completed suicide	72.25	12.05	4	28315	145916	46511827
Hepatic cancer	69.27	12.05	35	28284	3062	46654681
Thrombotic microangiopathy	67.54	12.05	49	28270	8257	46649486
Febrile neutropenia	66.83	12.05	165	28154	94462	46563281
Hyperbilirubinaemia	65.98	12.05	53	28266	10385	46647358
Interstitial lung disease	64.91	12.05	117	28202	53832	46603911
Renal impairment	62.69	12.05	139	28180	74233	46583510
Pyrexia	62.52	12.05	393	27926	348409	46309334
Cholestasis of pregnancy	62.16	12.05	24	28295	1100	46656643
Oesophageal varices haemorrhage	60.19	12.05	24	28295	1199	46656544
Acute graft versus host disease in skin	58.90	12.05	31	28288	2951	46654792
Neutrophil count decreased	58.51	12.05	99	28220	43327	46614416
Acute graft versus host disease	55.35	12.05	33	28286	3997	46653746
Autoimmune hepatitis	54.39	12.05	42	28277	7772	46649971
Cholangitis sclerosing	53.74	12.05	21	28298	994	46656749
Total bile acids increased	52.40	12.05	13	28306	128	46657615
Decreased appetite	51.27	12.05	243	28076	193593	46464150
Gamma-glutamyltransferase increased	50.44	12.05	78	28241	31662	46626081
Cytomegalovirus viraemia	49.66	12.05	32	28287	4446	46653297
Liver transplant rejection	47.47	12.05	21	28298	1362	46656381
Varices oesophageal	46.48	12.05	26	28293	2793	46654950
Venoocclusive disease	46.38	12.05	23	28296	1933	46655810
Stomatitis	46.00	12.05	117	28202	68180	46589563
Chronic graft versus host disease	44.57	12.05	25	28294	2700	46655043
Drug-induced liver injury	42.65	12.05	64	28255	25304	46632439
Drug intolerance	42.48	12.05	18	28301	147031	46510712
Joint swelling	42.41	12.05	24	28295	166049	46491694
Portal hypertension	41.39	12.05	26	28293	3457	46654286
Cytomegalovirus test positive	41.11	12.05	24	28295	2796	46654947
Anaemia	40.74	12.05	280	28039	255499	46402244
Pulmonary malformation	40.63	12.05	10	28309	95	46657648
Liver transplant	39.06	12.05	22	28297	2395	46655348
Hypoproteinaemia	38.81	12.05	20	28299	1823	46655920
Cystitis haemorrhagic	38.48	12.05	25	28294	3522	46654221
Contraindicated product administered	37.18	12.05	3	28316	79944	46577799
Pain in extremity	35.67	12.05	64	28255	258616	46399127
Adenoviral hepatitis	35.65	12.05	11	28308	254	46657489
Pancytopenia	35.54	12.05	123	28196	84935	46572808
Cystic fibrosis	35.20	12.05	24	28295	3664	46654079
White blood cell count decreased	34.35	12.05	147	28172	112084	46545659
Bile duct stone	34.13	12.05	23	28296	3444	46654299
Hepatomegaly	34.08	12.05	38	28281	11215	46646528
Sepsis	33.39	12.05	167	28152	135847	46521896
Respiratory tract malformation	32.99	12.05	8	28311	71	46657672
Injection site pain	32.77	12.05	12	28307	107140	46550603
Hypoalbuminaemia	32.06	12.05	35	28284	10092	46647651
Blood lactate dehydrogenase increased	32.04	12.05	50	28269	20450	46637293
Splenomegaly	31.57	12.05	34	28285	9654	46648089
Treatment failure	30.98	12.05	9	28310	93078	46564665
Therapy interrupted	30.24	12.05	35	28284	10756	46646987
Lung cyst	29.87	12.05	8	28311	109	46657634
Tonsillar haemorrhage	29.84	12.05	9	28310	192	46657551
Cardiac failure	29.48	12.05	111	28208	79837	46577906
Palmar-plantar erythrodysaesthesia syndrome	29.38	12.05	48	28271	20403	46637340
Hypersensitivity	29.03	12.05	29	28290	150292	46507451
Coagulation test abnormal	28.91	12.05	12	28307	665	46657078
Aplastic anaemia	28.56	12.05	28	28291	7125	46650618
Multiple organ dysfunction syndrome	28.21	12.05	82	28237	51628	46606115
Blood alkaline phosphatase abnormal	28.12	12.05	10	28309	363	46657380
Therapeutic product effect decreased	27.46	12.05	8	28311	82593	46575150
Staphylococcal sepsis	27.34	12.05	28	28291	7504	46650239
Pneumonia cytomegaloviral	26.79	12.05	16	28303	1944	46655799
Enterococcal sepsis	26.66	12.05	14	28305	1326	46656417
Bacterial sepsis	26.65	12.05	20	28299	3547	46654196
Hepatitis cholestatic	26.40	12.05	26	28293	6651	46651092
Hepatic necrosis	26.33	12.05	24	28295	5577	46652166
Intentional overdose	26.27	12.05	4	28315	64940	46592803
Acute graft versus host disease in intestine	26.24	12.05	15	28304	1680	46656063
Venous haemorrhage	26.04	12.05	8	28311	182	46657561
Hyperuricaemia	25.74	12.05	22	28297	4695	46653048
Pleural effusion	25.64	12.05	109	28210	82843	46574900
Vanishing bile duct syndrome	25.63	12.05	11	28308	663	46657080
Hepatitis fulminant	25.25	12.05	19	28300	3383	46654360
Hepatic fibrosis	25.10	12.05	18	28301	2977	46654766
Candida test positive	25.10	12.05	12	28307	931	46656812
Ammonia increased	25.09	12.05	21	28298	4356	46653387
Arthralgia	25.00	12.05	125	28194	364478	46293265
Haemophagocytic lymphohistiocytosis	24.97	12.05	28	28291	8314	46649429
Haemorrhage subcutaneous	23.30	12.05	17	28302	2889	46654854
Coma hepatic	23.25	12.05	10	28309	606	46657137
Engraftment syndrome	22.85	12.05	8	28311	277	46657466
Muscle spasms	22.36	12.05	25	28294	123088	46534655
Abdominal discomfort	22.09	12.05	36	28283	151129	46506614
Hepatitis C	22.06	12.05	23	28296	6295	46651448
Hyperammonaemia	21.76	12.05	20	28299	4696	46653047
Alopecia	21.63	12.05	41	28278	162373	46495370
Premature baby	21.41	12.05	39	28280	18073	46639670
Histoplasmosis	21.05	12.05	13	28306	1677	46656066
Cardiac tamponade	20.77	12.05	19	28300	4435	46653308
Enterocolitis	20.72	12.05	22	28297	6146	46651597
Chest pain	20.56	12.05	48	28271	176276	46481467
Overdose	20.46	12.05	19	28300	101960	46555783
Therapy cessation	20.45	12.05	48	28271	26581	46631162
Aspergillus infection	20.41	12.05	23	28296	6867	46650876
Injection site erythema	20.10	12.05	10	28309	74417	46583326
Spider naevus	20.07	12.05	6	28313	124	46657619
Loss of personal independence in daily activities	20.02	12.05	5	28314	57178	46600565
Maternal exposure during breast feeding	19.43	12.05	15	28304	2774	46654969
Adenovirus infection	19.24	12.05	15	28304	2815	46654928
Blood creatine phosphokinase increased	19.18	12.05	48	28271	27676	46630067
Cholangitis acute	19.13	12.05	8	28311	452	46657291
Altered state of consciousness	18.93	12.05	43	28276	23305	46634438
Osteoarthritis	18.87	12.05	7	28312	62018	46595725
Cytokine release syndrome	18.82	12.05	21	28298	6202	46651541
Swelling	18.81	12.05	29	28290	124482	46533261
Faeces soft	18.65	12.05	16	28303	3432	46654311
Arthritis	18.56	12.05	12	28307	77304	46580439
Chronic obstructive pulmonary disease	18.40	12.05	6	28313	57627	46600116
Premature labour	18.27	12.05	28	28291	11271	46646472
Fatigue	18.25	12.05	260	28059	608437	46049306
Blood albumin abnormal	18.10	12.05	7	28312	322	46657421
Acute myeloid leukaemia recurrent	18.06	12.05	11	28308	1385	46656358
Sinusitis	17.95	12.05	32	28287	129736	46528007
Enterocolitis bacterial	17.56	12.05	6	28313	193	46657550
Amylase increased	17.51	12.05	19	28300	5440	46652303
Hyperamylasaemia	17.31	12.05	7	28312	363	46657380
Asthma	17.28	12.05	18	28301	91524	46566219
Toxicity to various agents	17.27	12.05	68	28251	211698	46446045
Mucosal disorder	17.25	12.05	12	28307	1892	46655851
Foetor hepaticus	17.15	12.05	3	28316	3	46657740
Cholecystitis acute	17.14	12.05	22	28297	7516	46650227
Injection site reaction	17.11	12.05	4	28315	47845	46609898
Fixed eruption	17.11	12.05	9	28310	856	46656887
Spinal compression fracture	16.82	12.05	29	28290	12874	46644869
Hallucination, tactile	16.68	12.05	6	28313	225	46657518
Migraine	16.63	12.05	11	28308	70015	46587728
Acute graft versus host disease in liver	16.59	12.05	8	28311	632	46657111
Gait disturbance	16.57	12.05	40	28279	145223	46512520
Anxiety	16.43	12.05	56	28263	181901	46475842
Transfusion	16.29	12.05	29	28290	13202	46644541
Liver carcinoma ruptured	16.29	12.05	3	28316	5	46657738
Acute lymphocytic leukaemia recurrent	16.22	12.05	12	28307	2083	46655660
Ocular icterus	15.95	12.05	15	28304	3625	46654118
Anion gap normal	15.93	12.05	3	28316	6	46657737
Cerebrovascular accident	15.77	12.05	23	28296	101016	46556727
Hepatitis B	15.77	12.05	15	28304	3678	46654065
Depression	15.60	12.05	52	28267	170052	46487691
Cholelithiasis	15.34	12.05	55	28264	38626	46619117
Gastrointestinal mucosal disorder	15.32	12.05	8	28311	749	46656994
Injection site swelling	15.17	12.05	3	28316	40324	46617419
Myocarditis	15.16	12.05	21	28298	7718	46650025
Epstein-Barr virus associated lymphoproliferative disorder	15.01	12.05	10	28309	1469	46656274
Intraventricular haemorrhage neonatal	14.90	12.05	5	28314	152	46657591
Septic shock	14.84	12.05	72	28247	57821	46599922
Drug eruption	14.83	12.05	37	28282	21292	46636451
Oedema	14.81	12.05	80	28239	66991	46590752
Cholangitis infective	14.78	12.05	5	28314	156	46657587
Pregnancy	14.76	12.05	43	28276	27094	46630649
Liver injury	14.71	12.05	31	28288	15970	46641773
Hepatitis	14.69	12.05	48	28271	32167	46625576
Renal tubular disorder	14.49	12.05	12	28307	2453	46655290
Sopor	14.42	12.05	35	28284	19793	46637950
Pelvic venous thrombosis	14.31	12.05	10	28309	1587	46656156
Bronchopulmonary aspergillosis	14.18	12.05	20	28299	7476	46650267
Transposition of the great vessels	14.18	12.05	5	28314	177	46657566
Graft versus host disease in gastrointestinal tract	14.13	12.05	12	28307	2538	46655205
Dyspnoea	14.12	12.05	224	28095	515324	46142419
Viral haemorrhagic cystitis	13.92	12.05	7	28312	606	46657137
Hyponatraemia	13.82	12.05	107	28212	101225	46556518
Transplantation complication	13.80	12.05	4	28315	74	46657669
Musculoskeletal stiffness	13.70	12.05	24	28295	97969	46559774
Wrong technique in product usage process	13.68	12.05	8	28311	54414	46603329
Hepatic artery stenosis	13.54	12.05	3	28316	17	46657726
Biliary cirrhosis	13.50	12.05	4	28315	80	46657663
Immunosuppressant drug level increased	13.39	12.05	13	28306	3269	46654474
Myositis	13.36	12.05	20	28299	7884	46649859
Hepatic mass	13.32	12.05	9	28310	1353	46656390
Urine uric acid increased	13.26	12.05	3	28316	19	46657724
Septic arthritis staphylococcal	13.25	12.05	6	28313	411	46657332
Systemic lupus erythematosus	13.24	12.05	12	28307	65168	46592575
Portal hypertensive gastropathy	13.24	12.05	7	28312	672	46657071
Upper respiratory tract inflammation	13.18	12.05	12	28307	2783	46654960
Hypokalaemia	13.16	12.05	95	28224	87929	46569814
Haematuria	13.14	12.05	41	28278	26817	46630926
Renal glycosuria	13.13	12.05	3	28316	20	46657723
Off label use	13.11	12.05	312	28007	379529	46278214
Biliary tract disorder	13.08	12.05	7	28312	689	46657054
Dizziness	12.96	12.05	138	28181	340276	46317467
Serum ferritin increased	12.94	12.05	16	28303	5267	46652476
Erythema multiforme	12.90	12.05	22	28297	9682	46648061
Graft versus host disease in skin	12.84	12.05	11	28308	2356	46655387
Caesarean section	12.82	12.05	30	28289	16573	46641170
Epstein-Barr virus infection	12.68	12.05	18	28301	6766	46650977
VIIIth nerve lesion	12.65	12.05	3	28316	24	46657719
Myocardial infarction	12.65	12.05	25	28294	97503	46560240
Mucosal inflammation	12.64	12.05	52	28267	38924	46618819
Lower respiratory tract infection	12.62	12.05	9	28310	55080	46602663
Bile duct stenosis	12.53	12.05	8	28311	1093	46656650
Pneumonia fungal	12.51	12.05	14	28305	4146	46653597
Neutropenia	12.33	12.05	137	28182	143067	46514676
Feeling abnormal	12.32	12.05	37	28282	125023	46532720
Psoriasis	12.16	12.05	18	28301	78586	46579157
Corynebacterium sepsis	12.14	12.05	3	28316	29	46657714
Right atrial dilatation	12.09	12.05	6	28313	505	46657238

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	407.81	11.62	323	26806	41622	29883727
Hepatic encephalopathy	219.52	11.62	145	26984	14047	29911302
Hepatic cancer	185.77	11.62	99	27030	6449	29918900
Blood bilirubin increased	168.23	11.62	186	26943	36450	29888899
Hepatic failure	165.30	11.62	178	26951	33865	29891484
Liver disorder	154.21	11.62	161	26968	29561	29895788
Ascites	148.98	11.62	173	26956	35748	29889601
Infective pulmonary exacerbation of cystic fibrosis	145.83	11.62	93	27036	8479	29916870
Cholangitis	136.09	11.62	86	27043	7716	29917633
Venoocclusive liver disease	136.05	11.62	81	27048	6532	29918817
Palmar-plantar erythrodysaesthesia syndrome	118.13	11.62	102	27027	14768	29910581
Pyrexia	105.45	11.62	535	26594	293954	29631395
Hepatocellular carcinoma	95.31	11.62	75	27054	9535	29915814
Graft versus host disease	89.61	11.62	74	27055	10076	29915273
Platelet count decreased	89.40	11.62	254	26875	105875	29819474
Aspartate aminotransferase increased	82.17	11.62	179	26950	63243	29862106
Interstitial lung disease	80.39	11.62	172	26957	60025	29865324
Graft versus host disease in skin	74.58	11.62	43	27086	3264	29922085
Acute graft versus host disease in skin	74.33	11.62	48	27081	4468	29920881
Jaundice	74.07	11.62	117	27012	32369	29892980
Completed suicide	70.79	11.62	5	27124	99487	29825862
Acute graft versus host disease	69.71	11.62	51	27078	5813	29919536
Renal impairment	64.62	11.62	195	26934	83989	29841360
Cholangitis sclerosing	64.30	11.62	26	27103	894	29924455
Death	61.19	11.62	147	26982	357136	29568213
Cystitis haemorrhagic	60.02	11.62	43	27086	4744	29920605
Alanine aminotransferase increased	58.83	11.62	174	26955	74102	29851247
Disseminated intravascular coagulation	57.80	11.62	85	27044	22086	29903263
Cytomegalovirus infection	57.78	11.62	88	27041	23586	29901763
Toxicity to various agents	57.25	11.62	46	27083	177137	29748212
Chronic graft versus host disease	56.29	11.62	39	27090	4080	29921269
Myocardial infarction	55.79	11.62	22	27107	125603	29799746
Decreased appetite	55.22	11.62	275	26854	149635	29775714
Cytomegalovirus viraemia	53.15	11.62	43	27086	5686	29919663
Thrombotic microangiopathy	52.61	11.62	51	27078	8559	29916790
Dyspnoea	51.75	11.62	144	26985	333151	29592198
Gamma-glutamyltransferase increased	50.13	11.62	93	27036	29257	29896092
Oesophageal varices haemorrhage	49.16	11.62	32	27097	3019	29922330
Venoocclusive disease	48.82	11.62	30	27099	2560	29922789
Drug abuse	48.58	11.62	8	27121	82064	29843285
Febrile neutropenia	48.32	11.62	208	26921	106485	29818864
Acute graft versus host disease in liver	47.33	11.62	23	27106	1231	29924118
Drug-induced liver injury	46.25	11.62	75	27054	21199	29904150
Fatigue	45.81	11.62	144	26985	320529	29604820
Drug ineffective	45.78	11.62	157	26972	340230	29585119
Bile duct stone	44.15	11.62	27	27102	2284	29923065
Blood alkaline phosphatase increased	43.18	11.62	91	27038	31396	29893953
Engraftment syndrome	43.06	11.62	19	27110	814	29924535
White blood cell count decreased	42.98	11.62	170	26959	83777	29841572
Liver transplant rejection	42.81	11.62	26	27103	2172	29923177
Cholangitis acute	42.05	11.62	18	27111	716	29924633
Acute graft versus host disease in intestine	40.66	11.62	26	27103	2379	29922970
Hepatitis C	39.39	11.62	54	27075	13151	29912198
Hepatic cirrhosis	38.37	11.62	59	27070	15940	29909409
Hyperbilirubinaemia	35.84	11.62	59	27070	16883	29908466
Neutrophil count decreased	35.06	11.62	101	27028	42353	29882996
Dizziness	34.19	11.62	79	27050	194830	29730519
Cerebral infarction	33.61	11.62	74	27055	26299	29899050
Glomerulosclerosis	33.47	11.62	15	27114	667	29924682
Product dose omission issue	33.21	11.62	21	27108	91610	29833739
Amylase increased	30.90	11.62	32	27097	5809	29919540
Stomatitis	30.12	11.62	88	27041	37191	29888158
Liver carcinoma ruptured	29.62	11.62	9	27120	129	29925220
Pain	29.45	11.62	71	27058	172570	29752779
Hyperammonaemia	28.77	11.62	30	27099	5490	29919859
Anaemia	28.68	11.62	301	26828	207691	29717658
Cholelithiasis	28.36	11.62	59	27070	20166	29905183
Cerebrovascular accident	27.76	11.62	21	27108	83456	29841893
Blood lactate dehydrogenase increased	27.61	11.62	59	27070	20542	29904807
Intentional overdose	27.01	11.62	3	27126	41478	29883871
Eosinophilic colitis	26.88	11.62	9	27120	179	29925170
Hyperhidrosis	26.26	11.62	14	27115	67076	29858273
Altered state of consciousness	25.50	11.62	56	27073	19863	29905486
Hypoalbuminaemia	25.33	11.62	40	27089	11052	29914297
Cystic fibrosis related diabetes	25.28	11.62	8	27121	132	29925217
Graft versus host disease in liver	25.22	11.62	14	27115	988	29924361
Liver abscess	25.13	11.62	22	27107	3240	29922109
Anxiety	24.66	11.62	27	27102	89844	29835505
Overdose	24.65	11.62	24	27105	84313	29841036
Graft versus host disease in gastrointestinal tract	24.25	11.62	21	27108	3048	29922301
Liver transplant	23.83	11.62	20	27109	2782	29922567
Hepatorenal syndrome	23.61	11.62	19	27110	2492	29922857
Cardiac failure congestive	23.56	11.62	25	27104	84382	29840967
Coronary artery disease	23.23	11.62	8	27121	49704	29875645
Hyperuricaemia	23.21	11.62	31	27098	7363	29917986
Human herpesvirus 6 infection	23.20	11.62	17	27112	1941	29923408
Cytomegalovirus test positive	23.04	11.62	22	27107	3623	29921726
Fall	22.95	11.62	86	27043	181786	29743563
Joint swelling	22.92	11.62	7	27122	46939	29878410
Bile duct stenosis	22.54	11.62	14	27115	1217	29924132
Pleural effusion	22.50	11.62	129	27000	73937	29851412
Hemivertebra	22.50	11.62	7	27122	109	29925240
Enterocolitis	22.48	11.62	29	27100	6658	29918691
Discharge	22.15	11.62	7	27122	115	29925234
Stem cell transplant	21.92	11.62	17	27112	2114	29923235
Syncope	21.69	11.62	27	27102	84876	29840473
Viral haemorrhagic cystitis	21.59	11.62	12	27117	849	29924500
Aplasia	21.14	11.62	22	27107	4015	29921334
Drug eruption	21.01	11.62	48	27081	17478	29907871
Cystic fibrosis	20.95	11.62	17	27112	2257	29923092
Kidney fibrosis	20.08	11.62	16	27113	2069	29923280
Blood urea increased	19.77	11.62	68	27061	31313	29894036
Pulmonary alveolar haemorrhage	19.76	11.62	27	27102	6554	29918795
Peripheral swelling	19.50	11.62	16	27113	61058	29864291
Mucosal disorder	19.47	11.62	14	27115	1553	29923796
Autoimmune hepatitis	19.42	11.62	20	27109	3607	29921742
Haemobilia	19.41	11.62	8	27121	289	29925060
Hypoaldosteronism	19.30	11.62	7	27122	178	29925171
Pain in extremity	19.03	11.62	45	27084	110176	29815173
Pouchitis	18.81	11.62	10	27119	647	29924702
Hypotension	18.66	11.62	106	27023	200459	29724890
Rheumatoid arthritis	18.62	11.62	7	27122	41190	29884159
Adenovirus infection	18.41	11.62	21	27108	4247	29921102
Prothrombin level decreased	18.07	11.62	12	27117	1170	29924179
Proctitis haemorrhagic	18.02	11.62	3	27126	0	29925349
Blood albumin decreased	17.96	11.62	37	27092	12555	29912794
Psoriasis	17.95	11.62	8	27121	42498	29882851
Hepatic cancer recurrent	17.80	11.62	8	27121	358	29924991
Hyperplasia	17.69	11.62	9	27120	532	29924817
Cardiac disorder	17.66	11.62	7	27122	39886	29885463
Dilatation intrahepatic duct acquired	17.58	11.62	5	27124	56	29925293
Chronic obstructive pulmonary disease	17.50	11.62	10	27119	46116	29879233
Intentional product misuse	17.23	11.62	5	27124	34662	29890687
Erythema multiforme	17.14	11.62	28	27101	7957	29917392
C-reactive protein increased	16.83	11.62	81	27048	43392	29881957
Capillary leak syndrome	16.47	11.62	13	27116	1659	29923690
Varices oesophageal	16.40	11.62	18	27111	3491	29921858
Multiple organ dysfunction syndrome	16.38	11.62	106	27023	63381	29861968
Bronchopulmonary aspergillosis	16.25	11.62	35	27094	12249	29913100
Epstein-Barr virus associated lymphoproliferative disorder	16.09	11.62	13	27116	1715	29923634
Asthenia	16.05	11.62	126	27003	221164	29704185
Biliary tract infection	16.01	11.62	8	27121	455	29924894
Arthralgia	15.97	11.62	66	27063	135725	29789624
Cystitis viral	15.94	11.62	8	27121	459	29924890
Cholecystitis	15.90	11.62	30	27099	9549	29915800
Chest pain	15.90	11.62	54	27075	117573	29807776
Portal vein occlusion	15.89	11.62	5	27124	81	29925268
Oesophageal atresia	15.83	11.62	8	27121	466	29924883
Drug interaction	15.72	11.62	111	27018	199457	29725892
Memory impairment	15.69	11.62	7	27122	37167	29888182
Porphyria non-acute	15.58	11.62	8	27121	482	29924867
Faecalith	15.49	11.62	3	27126	4	29925345
Epstein-Barr virus infection	15.06	11.62	24	27105	6682	29918667
Portal vein thrombosis	14.87	11.62	17	27112	3447	29921902
Acute lymphocytic leukaemia recurrent	14.81	11.62	15	27114	2652	29922697
Feeling abnormal	14.54	11.62	18	27111	56738	29868611
Bacterial infection	14.52	11.62	34	27095	12576	29912773
Escherichia sepsis	14.50	11.62	18	27111	3976	29921373
Macroglossia	14.40	11.62	6	27123	223	29925126
Drug hypersensitivity	14.36	11.62	25	27104	68494	29856855
Pulmonary embolism	14.21	11.62	31	27098	78104	29847245
Antimitochondrial antibody positive	14.05	11.62	4	27125	45	29925304
Pancreatic enzymes increased	13.97	11.62	8	27121	599	29924750
Polychromasia	13.71	11.62	5	27124	129	29925220
Hepatic vein occlusion	13.68	11.62	5	27124	130	29925219
Staphylococcal sepsis	13.67	11.62	28	27101	9463	29915886
Tumour embolism	13.38	11.62	4	27125	54	29925295
Acute myocardial infarction	13.34	11.62	17	27112	52922	29872427
Vision blurred	13.29	11.62	11	27118	41805	29883544
Depression	13.27	11.62	40	27089	90397	29834952
Engraft failure	13.27	11.62	7	27122	446	29924903
Vanishing bile duct syndrome	13.26	11.62	8	27121	660	29924689
Cholestasis	13.13	11.62	51	27078	24899	29900450
Neonatal respiratory distress	13.05	11.62	7	27122	461	29924888
Cytomegalovirus duodenitis	12.93	11.62	4	27125	61	29925288
Bone marrow transplant	12.84	11.62	9	27120	959	29924390
Cytokine release syndrome	12.79	11.62	28	27101	9905	29915444
Haemophilic arthropathy	12.76	11.62	5	27124	158	29925191
Jaundice cholestatic	12.66	11.62	18	27111	4533	29920816
Headache	12.65	11.62	105	27024	182201	29743148
Hepatic vein stenosis	12.50	11.62	3	27126	16	29925333
Red blood cell schistocytes present	12.47	11.62	6	27123	314	29925035
Immunosuppressant drug level increased	12.21	11.62	18	27111	4684	29920665
Melanoderma	12.15	11.62	5	27124	180	29925169
Suicidal ideation	12.11	11.62	9	27120	36105	29889244
Drug intolerance	11.99	11.62	14	27115	45277	29880072
Musculoskeletal stiffness	11.95	11.62	9	27120	35872	29889477
Post transplant lymphoproliferative disorder	11.93	11.62	19	27110	5287	29920062
Transplant rejection	11.91	11.62	26	27103	9180	29916169
Lethargy	11.83	11.62	11	27118	39508	29885841
Cystic fibrosis hepatic disease	11.68	11.62	3	27126	22	29925327
Biliary tract disorder	11.63	11.62	8	27121	827	29924522

Pharmacologic Action:

Source	Code	Description
ATC	A05AA02	ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY BILE THERAPY Bile acids and derivatives
FDA CS	M0002475	Bile Acids and Salts
FDA EPC	N0000175802	Bile Acid
MeSH PA	D002756	Cholagogues and Choleretics
MeSH PA	D005765	Gastrointestinal Agents
CHEBI has role	CHEBI:75771	mus musculus metabolite
CHEBI has role	CHEBI:77746	h. sapiens metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Primary biliary cirrhosis	indication	31712002	DOID:12236
Calculus in biliary tract	indication	266474003
Cholelithiasis Prevention	indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.92	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN	AGONIST			CHEMBL	CHEMBL
Aldo-keto reductase family 1 member C2	Enzyme	P52895	AK1C2_HUMAN				WOMBAT-PK
G-protein coupled bile acid receptor 1	GPCR	Q8TDU6	GPBAR_HUMAN		EC50	5.62	CHEMBL
M1-family alanyl aminopeptidase	Unclassified		Q8IEK1_PLAF7		IC50	5.59	CHEMBL

External reference:

ID	Source
4019318	VUID
N0000147507	NUI
D00734	KEGG_DRUG
4019318	VANDF
C0042105	UMLSCUI
CHEBI:9907	CHEBI
CHEMBL1551	ChEMBL_ID
D014580	MESH_DESCRIPTOR_UI
4920	INN_ID
DB01586	DRUGBANK_ID
724L30Y2QR	UNII
31401	PUBCHEM_CID
7104	IUPHAR_LIGAND_ID
11065	RXNORM
31954	MMSL
5659	MMSL
d01005	MMSL
001212	NDDF
108669000	SNOMEDCT_US
41143004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Actigall	HUMAN PRESCRIPTION DRUG LABEL	1	0023-6145	CAPSULE	300 mg	ORAL	NDA	18 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1730	CAPSULE	300 mg	ORAL	ANDA	18 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1326	CAPSULE	300 mg	ORAL	ANDA	19 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2998	TABLET	250 mg	ORAL	NDA AUTHORIZED GENERIC	24 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3005	TABLET	500 mg	ORAL	NDA AUTHORIZED GENERIC	24 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3159	CAPSULE	300 mg	ORAL	NDA authorized generic	18 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0615-1374	CAPSULE	300 mg	ORAL	NDA	17 sections
Ursodiol 200 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0722-7143	CAPSULE	200 mg	ORAL	ANDA	19 sections
Ursodiol 400 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0722-7144	CAPSULE	400 mg	ORAL	ANDA	19 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6221	CAPSULE	300 mg	ORAL	ANDA	12 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6890	TABLET, FILM COATED	250 mg	ORAL	ANDA	24 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-543	CAPSULE	300 mg	ORAL	ANDA	18 sections
URSODIOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-349	CAPSULE	300 mg	ORAL	NDA	17 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	24658-780	CAPSULE	300 mg	ORAL	ANDA	12 sections
Ursodiol	Human Prescription Drug Label	1	42385-946	CAPSULE	300 mg	ORAL	ANDA	17 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	42806-503	CAPSULE	300 mg	ORAL	ANDA	12 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	49884-412	TABLET, FILM COATED	250 mg	ORAL	ANDA	24 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	49884-413	TABLET, FILM COATED	500 mg	ORAL	ANDA	24 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-796	CAPSULE	300 mg	ORAL	ANDA	12 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-797	CAPSULE	300 mg	ORAL	ANDA	17 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	51079-383	CAPSULE	300 mg	ORAL	ANDA	18 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	51224-151	CAPSULE	300 mg	ORAL	ANDA	19 sections
BAMBOO SALT Eunganggo Jook Yeom Toothpaste	HUMAN OTC DRUG LABEL	7	53208-459	PASTE	0.02 g	DENTAL	OTC monograph not final	4 sections
BAMBOO SALT Eunganggo Jook Yeom	HUMAN OTC DRUG LABEL	7	53208-505	PASTE	0.02 g	DENTAL	OTC monograph not final	8 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5033	CAPSULE	300 mg	ORAL	NDA AUTHORIZED GENERIC	17 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	55154-3355	CAPSULE	300 mg	ORAL	ANDA	12 sections
Urso 250	HUMAN PRESCRIPTION DRUG LABEL	1	58914-785	TABLET, FILM COATED	250 mg	ORAL	NDA	25 sections
Urso Forte	HUMAN PRESCRIPTION DRUG LABEL	1	58914-790	TABLET, FILM COATED	500 mg	ORAL	NDA	25 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	60429-662	CAPSULE	300 mg	ORAL	ANDA	18 sections
Ursodiol	HUMAN PRESCRIPTION DRUG LABEL	1	60687-100	CAPSULE	300 mg	ORAL	ANDA	19 sections